{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:11:56Z","timestamp":1793059916389,"version":"4.5.0"},"reference-count":32,"publisher":"Japanese Circulation Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2025,2,10]]},"DOI":"10.1253\/circrep.cr-24-0148","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T22:11:07Z","timestamp":1736287867000},"page":"97-105","source":"Crossref","is-referenced-by-count":1,"title":["Recent Trends in Achievement Rates and Time Required for Left Ventricular Reverse Remodeling in Dilated Cardiomyopathy"],"prefix":"10.1253","volume":"7","author":[{"given":"Masahiro","family":"Wanezaki","sequence":"first","affiliation":[{"name":"Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsu","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Iizuka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Edamura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Sugai","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harutoshi","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuhei","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoaki","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Otaki","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kutsuzawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehiko","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Arimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine"},{"name":"Department of Frontier Cardiovascular Science, The University of Tokyo Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Ko","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine"},{"name":"Department of Frontier Cardiovascular Science, The University of Tokyo Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seitaro","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine"},{"name":"Department of Frontier Cardiovascular Science, The University of Tokyo Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issei","family":"Komuro","sequence":"additional","affiliation":[{"name":"Department of Frontier Cardiovascular Science, The University of Tokyo Graduate School of Medicine"},{"name":"International University of Health and Welfare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: A Position Statement from the European Society of Cardiology Working Group on Myocardial and Pericardial diseases. <i>Eur Heart J<\/i> 2008; 29: 270\u2013276.","DOI":"10.1093\/eurheartj\/ehm342"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Bozkurt B, Colvin M, Cook J, Cooper LT, Deswal A, Fonarow GC, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: A Scientific Statement from the American Heart Association. <i>Circulation<\/i> 2016; 134: e579\u2013e646.","DOI":"10.1161\/CIR.0000000000000455"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC guidelines for the management of cardiomyopathies. <i>Eur Heart J<\/i> 2023; 44: 3503\u20133626.","DOI":"10.1093\/eurheartj\/ehad194"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Fukushima N, Ono M, Saiki Y, Sawa Y, Nunoda S, Isobe M. Registry report on heart transplantation in Japan (June 2016). <i>Circ J<\/i> 2017; 81: 298\u2013303.","DOI":"10.1253\/circj.CJ-16-0976"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Enzan N, Matsushima S, Ide T, Kaku H, Tohyama T, Funakoshi K, et al. Beta-blocker use is associated with prevention of left ventricular remodeling in recovered dilated cardiomyopathy. <i>J Am Heart Assoc<\/i> 2021; 10: e019240.","DOI":"10.1161\/JAHA.120.019240"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Di Lenarda A, Sinagra G. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. <i>J Am Coll Cardiol<\/i> 2011; 57: 1468\u20131476.","DOI":"10.1016\/j.jacc.2010.11.030"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kimura Y, Okumura T, Morimoto R, Kazama S, Shibata N, Oishi H, et al. A clinical score for predicting left ventricular reverse remodelling in patients with dilated cardiomyopathy. <i>ESC Heart Fail<\/i> 2021; 8: 1359\u20131368.","DOI":"10.1002\/ehf2.13216"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kinoshita M, Kato S, Kodama S, Azuma M, Nakayama N, Fukui K, et al. Native T1 heterogeneity for predicting reverse remodeling in patients with non-ischemic dilated cardiomyopathy. <i>Heart Vessels<\/i> 2022; 37: 1541\u20131550.","DOI":"10.1007\/s00380-022-02057-4"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Enzan N, Matsushima S, Ide T, Kaku H, Tohyama T, Funakoshi K, et al. The use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers is associated with the recovered ejection fraction in patients with dilated cardiomyopathy. <i>Int Heart J<\/i> 2021; 62: 801\u2013810.","DOI":"10.1536\/ihj.20-671"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Tsutsui H, Ide T, Ito H, Kihara Y, Kinugawa K, Kinugawa S, et al. JCS\/JHFS 2021 Guideline Focused Update on diagnosis and treatment of acute and chronic heart failure. <i>J Card Fail<\/i> 2021; 27: 1404\u20131444.","DOI":"10.1016\/j.cardfail.2021.04.023"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Duncker D, Konig T, Hohmann S, Bauersachs J, Veltmann C. Avoiding untimely implantable cardioverter\/defibrillator implantation by intensified heart failure therapy optimization supported by the wearable cardioverter\/defibrillator: The PROLONG study. <i>J Am Heart Assoc<\/i> 2017; 6: e004512.","DOI":"10.1161\/JAHA.116.004512"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kitaoka H, Tsutsui H, Kubo T, Ide T, Chikamori T, Fukuda K, et al. JCS\/JHFS 2018 Guideline on the diagnosis and treatment of cardiomyopathies. <i>Circ J<\/i> 2021; 85: 1590\u20131689.","DOI":"10.1253\/circj.CJ-20-0910"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Verdonschot JAJ, Hazebroek MR, Wang P, Sanders-van Wijk S, Merken JJ, Adriaansen YA, et al. Clinical phenotype and genotype associations with improvement in left ventricular function in dilated cardiomyopathy. <i>Circ Heart Fail<\/i> 2018; 11: e005220.","DOI":"10.1161\/CIRCHEARTFAILURE.118.005220"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Inoue S, Ko T, Shindo A, Nomura S, Yamada T, Jimba T, et al. Association between clonal hematopoiesis and left ventricular reverse remodeling in nonischemic dilated cardiomyopathy. <i>JACC Basic Transl Sci<\/i> 2024; 9: 956\u2013967.","DOI":"10.1016\/j.jacbts.2024.04.010"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Tsutsui H, Isobe M, Ito H, Okumura K, Ono M, Kitakaze M, et al. JCS 2017\/JHFS 2017 Guideline on diagnosis and treatment of acute and chronic heart failure. <i>Circ J<\/i> 2019; 83: 2084\u20132184.","DOI":"10.1253\/circj.CJ-19-0342"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Swat SA, Cohen D, Shah SJ, Lloyd-Jones DM, Baldridge AS, Freed BH, et al. Baseline longitudinal strain predicts recovery of left ventricular ejection fraction in hospitalized patients with nonischemic cardiomyopathy. <i>J Am Heart Assoc<\/i> 2018; 7: e09841.","DOI":"10.1161\/JAHA.118.009841"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. <i>Eur J Heart Fail<\/i> 2021; 23: 352\u2013380.","DOI":"10.1002\/ejhf.2115"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Tsutsui Y, Matsushima S, Enzan N, Noda E, Shinohara K, Hashimoto T, et al. Nationwide temporal trends in clinical characteristics and treatment of dilated cardiomyopathy from 2003 to 2013 in Japan: A report from clinical personal records. <i>Circ J<\/i> 2023; 87: 500\u2013507.","DOI":"10.1253\/circj.CJ-22-0554"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Bin Atan N, Bin Hadi MF, Teoh VWY, Danaee M, Loch A. ARNI versus perindopril for remodeling in HFrEF. A cohort study. <i>J Cardiovasc Pharmacol Ther<\/i> 2023; 28: 10742484231195019.","DOI":"10.1177\/10742484231195019"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Theofilis P, Antonopoulos AS, Katsimichas T, Oikonomou E, Siasos G, Aggeli C, et al. The impact of SGLT2 inhibition on imaging markers of cardiac function: A systematic review and meta-analysis. <i>Pharmacol Res<\/i> 2022; 180: 106243.","DOI":"10.1016\/j.phrs.2022.106243"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>Eur Heart J<\/i> 2023; 44: 3627\u20133639.","DOI":"10.1093\/eurheartj\/ehad195"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Park CS, Park JJ, Mebazaa A, Oh IY, Park HA, Cho HJ, et al. Characteristics, outcomes, and treatment of heart failure with improved ejection fraction. <i>J Am Heart Assoc<\/i> 2019; 8: e011077.","DOI":"10.1161\/JAHA.118.011077"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure: MOCHA investigators. <i>Circulation<\/i> 1996; 94: 2807\u20132816.","DOI":"10.1161\/01.CIR.94.11.2807"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: The multicenter carvedilol heart failure dose assessment (MUCHA) trial. <i>Am Heart J<\/i> 2004; 147: 324\u2013330.","DOI":"10.1016\/j.ahj.2003.07.023"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Okamoto H, Hori M, Matsuzaki M, Tsutsui H, Yamazaki T, Nagai R, et al. Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study. <i>Int J Cardiol<\/i> 2013; 164: 238\u2013244.","DOI":"10.1016\/j.ijcard.2012.11.051"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Lupon J, Gavidia-Bovadilla G, Ferrer E, de Antonio M, Perera-Lluna A, Lopez-Ayerbe J, et al. Dynamic trajectories of left ventricular ejection fraction in heart failure. <i>J Am Coll Cardiol<\/i> 2018; 72: 591\u2013601.","DOI":"10.1016\/j.jacc.2018.05.042"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Choi JO, Kim EY, Lee GY, Lee SC, Park SW, Kim DK, et al. Predictors of left ventricular reverse remodeling and subsequent outcome in nonischemic dilated cardiomyopathy. <i>Circ J<\/i> 2013; 77: 462\u2013469.","DOI":"10.1253\/circj.CJ-12-0507"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Kubanek M, Sramko M, Maluskova J, Kautznerova D, Weichet J, Lupinek P, et al. Novel predictors of left ventricular reverse remodeling in individuals with recent-onset dilated cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2013; 61: 54\u201363.","DOI":"10.1016\/j.jacc.2012.07.072"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Kawai K, Takaoka H, Hata K, Yokota Y, Yokoyama M. Prevalence, predictors, and prognosis of reversal of maladaptive remodeling with intensive medical therapy in idiopathic dilated cardiomyopathy. <i>Am J Cardiol<\/i> 1999; 84: 671\u2013676.","DOI":"10.1016\/S0002-9149(99)00414-2"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: A randomized clinical trial. <i>JAMA<\/i> 2017; 318: 713\u2013720.","DOI":"10.1001\/jama.2017.10565"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Stienen S, Salah K, Moons AH, Bakx AL, van Pol P, Kortz RAM, et al. NT-proBNP (N-terminal pro-B-type natriuretic peptide)-guided therapy in acute decompensated heart failure: PRIMA II randomized controlled trial (Can NT-proBNP-guided therapy during hospital admission for acute decompensated heart failure reduce mortality and readmissions?). <i>Circulation<\/i> 2018; 137: 1671\u20131683.","DOI":"10.1161\/CIRCULATIONAHA.117.029882"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. McLellan J, Bankhead CR, Oke JL, Hobbs FDR, Taylor CJ, Perera R. Natriuretic peptide-guided treatment for heart failure: A systematic review and meta-analysis. <i>BMJ Evid Based Med<\/i> 2020; 25: 33\u201337.","DOI":"10.1136\/bmjebm-2019-111208"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/7\/2\/7_CR-24-0148\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T03:28:16Z","timestamp":1739590096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/7\/2\/7_CR-24-0148\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-24-0148","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"article-number":"CR-24-0148"}}